2008-006903-22: Narrow band UV-B phototherapy and fluticasone proprionate versus narrow band UV-B phototherapy and placebo for the treatment of active vitiligo: a randomized double blind controlled trial |
|
|
| Ongoing | 4 | 64 | Europe | Cutivate, RVG06933, Cutivate, Cutivate | Academic Medical Center | Narrow band ultra violet B phototherapy is the gold standard for the treatment of vitiligo vulgaris. Ultra violet A and fluticasone proprionate (cutivate) together have shown significant better repigmentation than both treatments alone in a study by Westerhof et al in 1999. We expect that the combination of narrow band ultra violet B and fluticasone proprionate will have a significantly better result in terms of repigmentation for the treatment of vitiligo. | | | | |
ChiCTR2000031143: clinical trial of a long-term intermittent treatment of 0.05% fluticasone propionate cream to prevent recurrence of vitiligo |
|
|
| Recruiting | N/A | 192 | | Fluticasone propionate cream was used as a placebo for topical treatment once every Saturday and Sunday, and the duration of administration for 12 months. ;Topical rubbing with 0.05% fluticasone propionate cream (15g / stick, Aramco Pharmaceutical Co., Ltd., the same below), topical application once every Saturday and Sunday, maintaining medication for 3 months. ;Topical rubbing with 0.05% fluticasone propionate cream, topical application once every Saturday and Sunday, maintaining medication for 6 months. ;Topical rubbing with 0.05% fluticasone propionate cream, topical application once every Saturday and Sunday, maintaining medication for 12 months. | Dermatology Hospital, Southern Medical University; The Sixth Affiliated Hospital of Sun Yat-Sen University, Dermatology Hospital, Southern Medical University | vitiligo | | | | |
